It was demonstrated that genetically engineering hUMSCs to produce IL-18 had synergistic therapeutic benefits and that such cells could contribute to an adoptive immunotherapy for breast cancer and thereby provide a promising new treatment option. The gene discussed is IL18; the disease is breast carcinoma.